Business
Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH
Proceeds to primarily support MASH pipeline expansion and to refinance existing senior credit facility$350 million initial term loan funded at close and up to an additional $150 million available through 2027Agreement also provides for the possibility of additional incremental facilities of up to $250 million of credit to support further strategic pipeline expansion CONSHOHOCKEN, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company foc
About this update from Blue Owl Capital Inc.
[{"type":"image","alt":"Madrigal Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Madrigal Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":86,"url":"https://media.zenfs.com/en/globenewswire.com/0a35449b0ee323b8224d49bf845d4cf5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8bWqK589xSpgJhdPdvdrmw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0a35449b0ee323b8224d49bf845d4cf5","width":300,"height":86}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Proceeds to primarily support MASH pipeline expansion and to refinance existing senior credit facility","length":102,"tagName":"p"}]},{"val":[{"type":"text","content":"$350 million initial term loan funded at close and up to an additional $150 million available through 2027","length":106,"tagName":"p"}]},{"val":[{"type":"text","content":"Agreement also provides for the possibility of additional incremental facilities of up to $250 million of credit to support further strategic pipeline expansion","length":160,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":368,"olType":false},{"type":"text","content":"CONSHOHOCKEN, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it has entered into a $500 million senior secured credit facility with funds managed by Blue Owl Capital (NYSE: OWL), a leading alternative asset manager, to primarily advance Madrigal’s pipeline to further extend its leadership position in MASH.","length":497,"tagName":"p"},{"type":"text","content":"The non-dilutive financing consists of:","length":39,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"A $350 million initial term loan funded at closing, a portion of which was used to refinance Madrigal’s existing $115 million senior secured debt plus fees;","length":156,"tagName":"p"}]},{"val":[{"type":"text","content":"A $150 million delayed draw term loan facility (DDTL), available in multiple draws at Madrigal’s discretion through December 2027; and","length":134,"tagName":"p"}]},{"val":[{"type":"text","content":"An option for additional incremental facilities of up to $250 mi...